Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
08:30am, Thursday, 16'th Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therap
Tempus AI Hits $100—Are Shares Due for a Pullback?
01:49pm, Wednesday, 15'th Oct 2025
Tempus AI NASDAQ: TEM has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a who
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
08:30am, Wednesday, 15'th Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen
TEM Expands Partnership With Northwestern Medicine Amid AI Boom
09:46am, Friday, 10'th Oct 2025
Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
11:56am, Thursday, 09'th Oct 2025
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
08:30am, Thursday, 09'th Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Pr
Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall
08:24am, Thursday, 09'th Oct 2025
Tempus AI Inc (NASDAQ:TEM) has become one of 2025's most dramatic comeback stories. The stock soared past $100 this week, marking a new 52-week high and sending the market buzzing about the AI-powered
These 5 Beaten-Down Tech Stocks Could Catch Fire Next
05:48pm, Wednesday, 08'th Oct 2025
Short interest is a powerful market force that can not only cap gains but drive share prices lower, but not always. Sometimes, even the short sellers get things wrong.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.
3 Healthcare Stocks Using AI to Drive Growth
11:13am, Saturday, 27'th Sep 2025
Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industrie
What Are 2 Great Tech Stocks to Buy Right Now?
08:45am, Saturday, 27'th Sep 2025
There's no doubt about it. The technology sector has been a great place to invest for decades.
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
10:26am, Friday, 26'th Sep 2025
Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to G
Why Tempus AI Stock Is Plunging This Week
06:53pm, Thursday, 25'th Sep 2025
Prior to the start of this week, Tempus AI (TEM -2.55%) stock had locked in a 161% gain since the start of the year -- an impressive performance for the healthcare company that's pioneering artificial
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
09:35am, Tuesday, 23'rd Sep 2025
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
Overlooked Stock: TEM Taps All-Time High on FDA Clearance
04:30pm, Monday, 22'nd Sep 2025
Tempus AI's (TEM) RNA-based vitro diagnostic device got clearance from the FDA for use. The company reached record highs on Monday's session but pulled back by the closing bell.
